Evolution of the Average Target: United Therapeutics Corporation

Evolution of the Average Target - United Therapeutics Corporation

Evolution of the Target Price: United Therapeutics Corporation

Evolution of the Target Price - United Therapeutics Corporation

Changes in Analyst Recommendations: United Therapeutics Corporation

f1b3a7cf3596c6d72bbda420f13d18b.PgSuRRnSBg93ujlLy4Jelc-1P_aVPJl1sI8wCasc7rY.WFzhcGiKWXlBw3Emu_Zt06XbRY7aa_FB5PtzRcgtj9cMUOkCVoRQbjv_dA~e7cc117540172da87e94e89f7008fcc3
10-08 RBC Raises Price Target on United Therapeutics to $708 From $677, Keeps Outperform Rating MT
10-01 Liquidia Shares Drop After Downgrades From Raymond James, BTIG MT
10-01 BTIG Upgrades United Therapeutics to Buy From Neutral, Price Target is $728 MT
08-06 MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says MT
08-06 United Therapeutics' Q2 Tyvaso Miss Reflects Competition; IPF Outreach Set to Expand, Morgan Stanley Says MT
08-06 RBC Capital Adjusts PT on United Therapeutics to $677 From $704, Maintains Outperform Rating MT
08-06 Morgan Stanley Adjusts PT on United Therapeutics to $515 From $516, Maintains Equalweight Rating MT
07-10 Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says MT
07-10 BofA Securities Adjusts United Therapeutics Price Target to $613 From $620 MT
07-07 RBC Capital Raises United Therapeutics Price Target to $704 From $701, Maintains Outperform Rating MT
06-30 United Therapeutics IPF Opportunity Outweighs Base Business Risks, UBS Says MT
05-07 United Therapeutics Growth Outlook Remains Supported by Tyvaso, Ralinepag, RBC Says MT
05-07 RBC Capital Adjusts United Therapeutics Price Target to $701 From $707, Maintains Outperform Rating MT
05-07 Wells Fargo Upgrades United Therapeutics to Overweight From Equalweight, Raises Price Target to $738 From $575 MT
05-07 Morgan Stanley Trims Price Target on United Therapeutics to $516 From $519, Keeps Equalweight Rating MT
04-10 Raymond James Initiates United Therapeutics at Outperform MT
04-07 RBC Capital Adjusts Price Target on United Therapeutics to $700 From $643, Maintains Outperform Rating MT
03-05 United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says MT
03-05 UBS Adjusts Price Target on United Therapeutics to $705 From $655, Maintains Buy Rating MT
02-26 United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says MT
02-26 Oppenheimer Adjusts United Therapeutics Price Target to $600 From $575, Maintains Outperform Rating MT
02-26 RBC Raises Price Target on United Therapeutics to $643 From $587, Keeps Outperform Rating MT
01-06 UBS Adjusts Price Target on United Therapeutics to $645 From $600, Maintains Buy Rating MT
11-06 UBS Adjusts Price Target on United Therapeutics to $600 From $580, Maintains Buy Rating MT
25-10-31 Analyst recommendations: Comcast, Roblox, Alphabet, Reddit, Western Digital… Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+23.22%
+5.65%
+9.33%
-0.99%
-0.52%
+8.56%
-0.8%
+26.78%
-8.67%
+2.34%
Average +6.49%
Weighted average by Cap. +5.07%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
533.12USD
Average target price
656.93USD
Spread / Average Target
+23.22%
High Price Target
728.00USD
Spread / Highest target
+36.55%
Low Price Target
368.00USD
Spread / Lowest Target
-30.97%

Analyst Consensus Detail

Analyst consensus - United Therapeutics Corporation

Consensus revision (last 18 months)

Consensus revision (last 18 months) - United Therapeutics Corporation
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - United Therapeutics Corporation
  1. Stock Market
  2. Stocks
  3. UTHR Stock
  4. Consensus United Therapeutics Corporation